GO:0032375 negative regulation of cholesterol transport: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032375 (negative regulation of cholesterol transport) describes any process that stops, prevents, or reduces the directed movement of cholesterol into, out of, or within cells.
• Cholesterol transport is essential for membrane integrity, steroid hormone synthesis, bile acid production, and lipoprotein metabolism.
• Negative regulation of cholesterol transport is critical for preventing cholesterol accumulation, which can lead to atherosclerosis, gallstones, and metabolic disorders.
• Key molecular players include NPC1L1, ABCA1, ABCG1, SR-BI, PCSK9, and GRAMD1C, which modulate cholesterol flux at the cellular level.
• Dysregulation of cholesterol transport is linked to Alagille syndrome, cardiovascular disease, and immune dysfunction.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of negative regulatory mechanisms in cholesterol transport.
Description
Cholesterol is an indispensable lipid that maintains membrane fluidity, serves as a precursor for steroid hormones and bile acids, and facilitates lipid raft signaling. The directed movement of cholesterol into, out of, and between cells is tightly controlled by a network of transporters, binding proteins, and regulatory feedback loops. GO:0032375, negative regulation of cholesterol transport, captures the biological processes that attenuate or inhibit this movement, thereby preventing excessive cholesterol accumulation and maintaining cellular homeostasis. Understanding this term is essential for researchers studying atherosclerosis, metabolic syndrome, and immune regulation, as well as for developing therapeutic strategies that target cholesterol flux. This article integrates authoritative QuickGO data with verified PubMed literature to provide a comprehensive overview of the mechanisms, genes, and experimental models relevant to GO:0032375.
negative regulation of cholesterol transport At A Glance
| GO ID | GO:0032375 |
|---|---|
| GO term | negative regulation of cholesterol transport |
| Ontology | biological_process |
| Synonym | down regulation of cholesterol transport, down-regulation of cholesterol transport, downregulation of cholesterol transport, inhibition of cholesterol transport |
| Major function | Attenuation of directed cholesterol movement into, out of, or within cells, or between cells |
| Related processes | Cholesterol homeostasis, lipoprotein metabolism, bile acid synthesis, steroidogenesis |
| Key regulators | NPC1L1, ABCA1, ABCG1, SR-BI, PCSK9, GRAMD1C, AQP8 |
| Disease relevance | Atherosclerosis, gallstone formation, Alagille syndrome, immune dysfunction |
What Is GO:0032375?
GO:0032375 (negative regulation of cholesterol transport) is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the directed movement of cholesterol into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. This term encompasses molecular mechanisms that inhibit cholesterol transport, including feedback repression of transporter expression, post-translational modification of transport proteins, and sequestration of cholesterol in intracellular compartments.
Why Is negative regulation of cholesterol transport Important in Cell Biology?
Negative regulation of cholesterol transport is vital for preventing cellular cholesterol overload, which can disrupt membrane integrity, trigger inflammation, and promote disease. In hepatocytes, negative regulation of cholesterol transport contributes to bile dilution and prevents gallstone formation. In the immune system, T cell cholesterol transport is linked to intestinal immune responses and dietary lipid absorption. Impaired negative feedback of cholesterol regulation is observed in Alagille syndrome, highlighting its clinical significance. Thus, understanding GO:0032375 provides insights into fundamental cell biology and offers therapeutic targets for metabolic and cardiovascular diseases.
• Prevents cholesterol accumulation in macrophages, reducing foam cell formation and atherosclerosis.
• Regulates bile cholesterol content, preventing gallstone formation.
• Modulates T cell function and intestinal immune responses to dietary lipids.
• Controls steroid hormone synthesis by limiting cholesterol availability in endocrine tissues.
• Impacts lipoprotein metabolism and plasma cholesterol levels.
• Dysregulation is linked to Alagille syndrome and other cholestatic liver diseases.
• Influences autophagosome biogenesis and mitochondrial bioenergetics via GRAMD1C.
• Provides targets for PCSK9 inhibitors and other lipid-lowering therapies.
• Affects transient receptor potential ion channel function through cholesterol modulation.
• Critical for maintaining neuronal membrane cholesterol homeostasis.
What Happens During negative regulation of cholesterol transport?
Feedback Repression of Cholesterol Transporters
In simple terms: When cells have enough cholesterol, they turn down the production of proteins that bring more cholesterol in.
Negative regulation of cholesterol transport often begins with sensing of excess cholesterol, which triggers transcriptional repression of genes encoding cholesterol importers such as NPC1L1 and LDL receptor. This feedback loop reduces cholesterol uptake and prevents overload. In Alagille syndrome, this negative feedback is impaired, leading to unchecked cholesterol transport.
Post-Translational Modification of Transport Proteins
In simple terms: Cells can modify existing transport proteins to make them less active or target them for degradation.
Phosphorylation, ubiquitination, and proteolytic cleavage of cholesterol transporters can inhibit their activity. For example, PCSK9 promotes degradation of LDL receptor, effectively reducing cholesterol transport into cells. Similarly, GRAMD1C is regulated by autophagic machinery, affecting its role in cholesterol transport.
Sequestration and Efflux Promotion
In simple terms: Cells can lock cholesterol away inside compartments or pump it out to reduce transport to other organelles.
Negative regulation of cholesterol transport includes mechanisms that sequester cholesterol in lysosomes or lipid droplets, and promote efflux via ABCA1 and ABCG1. Active cholesterol in the plasma membrane can signal to reduce further transport and enhance efflux. This prevents cholesterol from reaching sensitive organelles like mitochondria.
Regulation by Bile Acids and Nuclear Receptors
In simple terms: Bile acids and nuclear receptors act as signals to slow down cholesterol transport when levels are high.
Bile acids activate FXR, which represses cholesterol transport genes and stimulates efflux. In hepatocytes, aquaporin 8-mediated water transport facilitates bile dilution, indirectly regulating cholesterol transport and preventing gallstone formation. This nuclear receptor pathway is a key negative regulator of cholesterol transport.
Immune Cell-Specific Regulation
In simple terms: Immune cells have special ways to control cholesterol movement to balance activation and tolerance.
In T cells, cholesterol transport is linked to intestinal immune responses and dietary lipid absorption. Negative regulation of cholesterol transport in T cells may prevent excessive activation and maintain immune homeostasis. This highlights cell-type-specific mechanisms within GO:0032375.
Key Genes Involved in GO:0032375 negative regulation of cholesterol transport
The following genes and proteins are experimentally validated regulators of negative regulation of cholesterol transport (GO:0032375).
| Gene | Major Role | Research Relevance |
|---|---|---|
| NPC1L1 | Cholesterol importer; negative regulation reduces uptake | Target for ezetimibe; studied in intestinal cholesterol absorption |
| ABCA1 | Cholesterol efflux pump; negative regulation limits efflux | Mutations cause Tangier disease; key in HDL biogenesis |
| ABCG1 | Cholesterol efflux pump; negative regulation reduces efflux | Modulates macrophage cholesterol efflux |
| SR-BI | Selective cholesterol uptake; negative regulation reduces uptake | Receptor for HDL; studied in steroidogenesis |
| PCSK9 | Promotes LDL receptor degradation; negative regulation of transport | Target of evolocumab; regulates plasma cholesterol |
| GRAMD1C | Cholesterol transport protein; negative regulation affects autophagy | Links cholesterol transport to mitochondrial bioenergetics |
| AQP8 | Water transport; facilitates bile dilution; negative regulation of cholesterol transport | Prevents gallstone formation in mice |
| FXR | Nuclear receptor; represses cholesterol transport genes | Regulates bile acid and cholesterol homeostasis |
| LXR | Nuclear receptor; promotes efflux and inhibits uptake | Key regulator of reverse cholesterol transport |
| NPC1 | Lysosomal cholesterol exporter; negative regulation causes accumulation | Mutations cause Niemann-Pick type C |
| NPC2 | Lysosomal cholesterol binding protein; negative regulation impairs export | Defects lead to cholesterol accumulation |
| Caveolin-1 | Cholesterol binding protein; negative regulation affects transport | Involved in cholesterol trafficking and signaling |
| Annexin A2 | Cholesterol binding; negative regulation modulates transport | Role in membrane repair and cholesterol homeostasis |
| TRPV1 | Ion channel modulated by cholesterol; negative regulation affects activity | Cholesterol regulation of ion channels |
| TRPM8 | Ion channel modulated by cholesterol; negative regulation affects activity | Cholesterol regulation of ion channels |
| Heparin-like molecules | Modulate LDL regulation of PCSK9 uptake | Cell-associated heparin-like molecules affect cholesterol transport |
How Is negative regulation of cholesterol transport Regulated?
Negative regulation of cholesterol transport is controlled by multiple signaling pathways. The sterol regulatory element-binding protein (SREBP) pathway senses cholesterol levels and represses transcription of cholesterol transporters when cholesterol is abundant. Liver X receptors (LXRs) promote cholesterol efflux and inhibit uptake, acting as negative regulators of transport. The farnesoid X receptor (FXR) is activated by bile acids and represses cholesterol transport genes in the liver. Additionally, PCSK9-mediated degradation of LDL receptor reduces cholesterol uptake. Autophagic pathways regulate GRAMD1C, affecting cholesterol transport to mitochondria. These regulatory layers ensure tight control of cholesterol flux.
negative regulation of cholesterol transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PCSK9 | Hypercholesterolemia, atherosclerosis | Knockout mouse, overexpression in hepatocytes |
| AQP8 | Gallstone formation | Knockout mouse, bile duct ligation |
| JAG1 | Alagille syndrome | Patient-derived hepatocytes, knock-in mouse |
| GRAMD1C | Autophagy and mitochondrial bioenergetics | Knockout cell lines, overexpression |
| ABCA1 | Tangier disease, HDL deficiency | Knockout mouse, point mutation knock-in |
Atherosclerosis and Cardiovascular Disease
Impaired negative regulation of cholesterol transport leads to cholesterol accumulation in macrophages, foam cell formation, and atherosclerosis. PCSK9 gain-of-function mutations reduce LDL receptor levels, increasing plasma cholesterol and cardiovascular risk. Therapies targeting PCSK9 enhance negative regulation of cholesterol transport and lower LDL cholesterol.
Gallstone Disease
Aquaporin 8-mediated water transport facilitates bile dilution and prevents gallstone formation in mice. Negative regulation of cholesterol transport in hepatocytes is critical for maintaining bile cholesterol solubility; its impairment promotes cholesterol gallstones.
Alagille Syndrome
Alagille syndrome is a genetic disorder characterized by cholestasis and impaired negative feedback of cholesterol regulation in the liver. Patients exhibit dysregulated cholesterol transport, contributing to liver damage and metabolic complications.
Immune Dysfunction and Intestinal Inflammation
T cell cholesterol transport links intestinal immune responses to dietary lipid absorption. Negative regulation of cholesterol transport in T cells may prevent excessive immune activation and maintain intestinal homeostasis. Dysregulation could contribute to inflammatory bowel diseases.
From negative regulation of cholesterol transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of AQP8 impair negative regulation of cholesterol transport and promote gallstones? | AQP8 knockout mouse |
| Can point mutation in PCSK9 alter LDL receptor degradation? | PCSK9 point mutation knock-in mouse |
| Does overexpression of ABCA1 enhance cholesterol efflux? | ABCA1 overexpression in hepatocytes |
| What is the role of GRAMD1C in autophagosome biogenesis? | GRAMD1C knockout and tagged knock-in cell lines |
| How does T cell-specific cholesterol transport affect intestinal immunity? | Conditional knockout mouse |
| Does FXR activation repress cholesterol transport genes? | FXR knockout mouse, luciferase reporter |
How to Study the negative regulation of cholesterol transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Expression of cholesterol transport genes | Identify transcriptional repression |
| Proteomics | Protein abundance and modifications | Detect ubiquitination of transporters |
| Lipidomics | Cholesterol species and distribution | Quantify cholesterol accumulation |
| BODIPY-cholesterol imaging | Real-time cholesterol trafficking | Visualize transport inhibition |
| Cholesterol efflux assay | Rate of cholesterol efflux | Assess ABCA1 function |
| LDL uptake assay | Rate of cholesterol uptake | Measure PCSK9 effects |
| Bile cholesterol analysis | Bile cholesterol saturation | Study gallstone formation |
| Autophagosome flux assay | Autophagic activity | Link GRAMD1C to transport |
Transcriptomic Analysis of Cholesterol Transport Genes
RNA-seq can quantify expression of genes involved in negative regulation of cholesterol transport, such as ABCA1, ABCG1, and PCSK9, under different cholesterol conditions. This reveals transcriptional feedback mechanisms.
Proteomic and Lipidomic Profiling
Mass spectrometry-based proteomics and lipidomics measure cholesterol transport protein abundance and cholesterol species, identifying post-translational modifications that inhibit transport.
Imaging Cholesterol Trafficking
Fluorescent cholesterol analogs (e.g., BODIPY-cholesterol) and live-cell imaging track cholesterol movement and its negative regulation in real time.
Functional Transport Assays
Cholesterol efflux and uptake assays using radiolabeled cholesterol or fluorescent probes quantify the rate of transport and its inhibition.
How CRISPR Can Be Used to Study GO:0032375 negative regulation of cholesterol transport
Knockout
CRISPR knockout of genes such as ABCA1, ABCG1, or AQP8 can abolish negative regulation of cholesterol transport, leading to cholesterol accumulation and disease phenotypes. These models help identify essential regulators.
Point Mutation
Introducing point mutations in PCSK9 or NPC1L1 via CRISPR can mimic human variants that impair negative regulation of cholesterol transport, enabling structure-function studies.
Knock-in
Knock-in of tagged versions of GRAMD1C or ABCA1 allows tracking of protein localization and interaction during negative regulation of cholesterol transport.
Overexpression
CRISPR activation or transgenic overexpression of negative regulators like LXR or FXR can enhance repression of cholesterol transport, providing gain-of-function models.
How EDITGENE Supports negative regulation of cholesterol transport Research
Researchers studying negative regulation of cholesterol transport-related genes often need to determine whether a candidate gene is causally involved in inhibiting cholesterol movement, and which molecular mechanisms mediate this effect. EDITGENE provides comprehensive CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cholesterol transport research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NFKBIA Knockout HEK293 Cell Line | EDJ-KQ580 | Human | 4792 | Details Get a Quote |
| APOA2 Knockout HEK293 Cell Line | EDJ-KQ4066 | Human | 336 | Details Get a Quote |
| NFKBIA Knockout A-549 Cell Line | EDJ-KQ18991 | Human | 4792 | Details Get a Quote |
| NFKBIA Knockout HCT 116 Cell Line | EDJ-KQ18992 | Human | 4792 | Details Get a Quote |
| NFKBIA Knockout HeLa Cell Line | EDJ-KQ18993 | Human | 4792 | Details Get a Quote |
| APOA2 Knockout HCT 116 Cell Line | EDJ-KQ25098 | Human | 336 | Details Get a Quote |
| APOA2 Knockout Hep-G2 Cell Line | EDJ-KZ545 | Human | 336 | Details Get a Quote |
| APOC1 Knockout HEK293 Cell Line | EDJ-KQ50124 | Human | 341 | Details Get a Quote |
| APOC2 Knockout HEK293 Cell Line | EDJ-KQ50125 | Human | 344 | Details Get a Quote |
| APOA2 Knockout HeLa Cell Line | EDJ-KQ52630 | Human | 336 | Details Get a Quote |
| APOC1 Knockout HeLa Cell Line | EDJ-KQ52634 | Human | 341 | Details Get a Quote |
| APOC2 Knockout HeLa Cell Line | EDJ-KQ52636 | Human | 344 | Details Get a Quote |
| APOA2 Knockout A-549 Cell Line | EDJ-KQ61105 | Human | 336 | Details Get a Quote |
| APOC1 Knockout A-549 Cell Line | EDJ-KQ61109 | Human | 341 | Details Get a Quote |
| APOC2 Knockout A-549 Cell Line | EDJ-KQ61111 | Human | 344 | Details Get a Quote |
Frequently Asked Questions About negative regulation of cholesterol transport
What is negative regulation of cholesterol transport?
It is any process that stops, prevents, or reduces the directed movement of cholesterol into, out of, or within cells, or between cells, as defined by GO:0032375.
What genes are involved in negative regulation of cholesterol transport?
Key genes include ABCA1, ABCG1, PCSK9, GRAMD1C, AQP8, FXR, and LXR, among others.
How is cholesterol transport negatively regulated?
Through feedback repression of transporters, post-translational modifications, sequestration, and nuclear receptor signaling.
Why is negative regulation of cholesterol transport important?
It prevents cholesterol overload, which can cause atherosclerosis, gallstones, and metabolic disorders.
What diseases are linked to impaired negative regulation of cholesterol transport?
Atherosclerosis, gallstone disease, Alagille syndrome, and immune dysfunction.
What experimental models are used to study negative regulation of cholesterol transport?
Knockout mice, point mutation knock-ins, overexpression cell lines, and CRISPR screens.
How does PCSK9 regulate cholesterol transport?
PCSK9 promotes degradation of LDL receptor, reducing cholesterol uptake into cells.
What is the role of GRAMD1C in cholesterol transport?
GRAMD1C regulates autophagosome biogenesis and mitochondrial bioenergetics, affecting cholesterol transport.
Can CRISPR be used to study negative regulation of cholesterol transport?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of regulatory mechanisms.
What methods measure negative regulation of cholesterol transport?
RNA-seq, proteomics, lipidomics, imaging, and functional transport assays.
Conclusion
GO:0032375 (negative regulation of cholesterol transport) is a critical biological process that maintains cholesterol homeostasis by attenuating the movement of cholesterol within and between cells. Dysregulation of this process contributes to atherosclerosis, gallstone disease, Alagille syndrome, and immune dysfunction. Advances in CRISPR-based models and multi-omics approaches are unraveling the complex regulatory networks involved. EDITGENE provides essential tools and services to accelerate research in this field, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Norum KR et al.. 1983. Transport of cholesterol.. Physiol Rev 63(4):1343-419 PMID: 6361811
- 2. Gao Y et al.. 2025. T cell cholesterol transport links intestinal immune responses to dietary lipid absorption.. Science 390(6769):eadt4169 PMID: 41066556
- 3. Charsou C et al.. 2023. Regulation of autophagosome biogenesis and mitochondrial bioenergetics by the cholesterol transport protein GRAMD1C.. Autophagy 19(7):2159-2161 PMID: 36469687
- 4. Lange Y et al.. 2024. How active cholesterol coordinates cell cholesterol homeostasis: Test of a hypothesis.. Prog Lipid Res 96:101304 PMID: 39491591
- 5. Huo X et al.. 2025. Hepatocyte aquaporin 8-mediated water transport facilitates bile dilution and prevents gallstone formation in mice.. J Hepatol 82(3):464-479 PMID: 39326676
- 6. Morales-Lázaro SL et al.. 2017. Multiple Mechanisms of Regulation of Transient Receptor Potential Ion Channels by Cholesterol.. Curr Top Membr 80:139-161 PMID: 28863814
- 7. Galvan AM et al.. 2019. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.. J Lipid Res 60(1):71-84 PMID: 30463987
- 8. Miyahara Y et al.. 2015. Negative feedback loop of cholesterol regulation is impaired in the livers of patients with Alagille syndrome.. Clin Chim Acta 440:49-54 PMID: 25444747
